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o address the heart failure burden, our focus needs to shift to disease prevention. Strategies to initially
creen for heart failure precursors such as asymptomatic left ventricular systolic dysfunction have been
valuated, including clinical scores, the 12-lead electrocardiogram, and natriuretic peptides. However,
heir specificity limits their broadapplicationas screening tools in asymptomaticpopulations.High-quality
mages are now available from hand-carried cardiac ultrasound devices, at a fraction of the capital cost of
tandard echocardiography with favorable diagnostic performance, especially when experienced staff
erform the imaging. Questions that remain to be addressed include how we should select the target
opulation to screen, who should perform the screening studies, howmuch training is required, and how
ften screening studies should be performed. (J Am Coll Cardiol Img 2010;3:421–8) © 2010 by the
merican College of Cardiology FoundationT
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f Quespite modest reductions in mortality over
he last 2 decades, there has been little
hange in the age-adjusted incidence of heart
ailure in community-based cohorts; hence,
verall and age-adjusted prevalence rates
ontinue to rise (1,2). Current treatment
trategies are usually applied at later stages in
he disease trajectory, with modest health
utcome gains. Our focus needs to shift to an
arlier stage, to allow disease prevention and
arly detection of patients before they de-
elop clinical congestive heart failure. Echo-
ardiographic markers associated with an
ncreased risk of developing heart failure
nclude left ventricular systolic dysfunction
LVSD), left ventricular (LV) diastolic dys-
unction, increased LV mass, and increased
eft atrial size (3–5). This review will focus
n asymptomatic LVSD, which holds the
ost promise as a potentially modifiable
chocardiographic risk factor.
rom the Royal Brisbane and Women’s Hospital and University oanuscript received September 17, 2009; revised manuscript receivedhe Diagnostic Assessment Framework: How
houldWe Evaluate the Benefit of
iagnostic Tests?
n ideal diagnostic test should be safe, accu-
ate, clinically effective, and cost effective.
ineberg et al. (6) initially proposed a hierar-
hic approach to the evaluation of diagnostic
maging technologies subsequently extended by
thers, including appraisal of technical efficacy,
iagnostic accuracy, impact on diagnostic
hinking, therapeutic planning and patient out-
omes, and societal considerations (7). Diag-
ostic accuracy refers to the ability of the test to
istinguish the presence or absence of disease.
elevant measures include sensitivity, specific-
ty, and measures related to receiver-operator-
haracteristic curves. To be clinically effective,
he information provided by the test should
esult in a change in both the clinician’s diag-
ostic thinking (by raising or lowering pre-test
eensland, Brisbane, Queensland, Australia.October 30, 2009, accepted November 12, 2009.
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422iagnostic probabilities) and subsequent therapeutic
lanning (by adding, changing, or removing treat-
ents) and henceforth overall improved health
utcomes.
Ideally the impact of a diagnostic test on clinical
utcomes is directly assessed in a randomized con-
rolled trial. This approach is least prone to system-
tic bias and allows evaluation of both the benefits
f identifying subclinical disease and dangers of
erforming diagnostic imaging whether directly
elated to the test or through the detection of
ontarget findings (8). However, such studies may
ot be feasible for ethical or logistic reasons, and
heir selected design may limit our ability to trans-
ate any observed treatment efficacy to clinical
ffectiveness in a broader population. Furthermore,
he time required to perform such studies may limit
heir relevance given the rapid evolution of new
echnologies (8). Alternatively, if there is evidence
rom adequately powered randomized controlled
rials that treatment of cases leads to better out-
comes, one may be able to link this to
evidence from diagnostic accuracy studies
to infer clinical effectiveness with a few
important caveats (Fig. 1) (9). First, the
diagnostic test should be applied at a
similar stage in the diagnostic pathway
and to a similar population as the subjects
assessed in the diagnostic accuracy studies.
Second, the cases identified by the diag-
nostic test should represent the same spec-
trum of disease as those subjects shown to
benefit in the treatment efficacy studies.
Societal considerations include equity, access,
nd economic impact. The seemingly exponential
ise in health care expenditure on the background of
onstrained clinical and economic resources has
ocused our attention on the evaluation of cost
ffectiveness, using metrics such as cost per case
iagnosed and cost per quality-adjusted life year
ained. The input variables may be obtained from
andomized trials or a decision analytic approach
hat combines diagnostic accuracy, treatment effi-
acy, and health resource utilization data from
ifferent sources. When it is not economically viable
o apply a test to a broad population, we may be able
o identify subgroups in which the clinical and cost
ffectiveness are maximized.
Before advocating a screening program, we need
o quantify the disease burden, identify whether
vailable treatments lead to better outcomes, and
etermine whether safe and effective diagnostic
ng
licesting strategies are available. that Is the Prevalence of Asymptomatic LVSD?
sing the heart failure classification proposed by
he American College of Cardiology and the Amer-
can Heart Association, asymptomatic structural
eart disease (stage B) was 2.8-fold more common
han symptomatic heart failure (stages C and D) in
community-based sample of residents age 45
ears (10). This forms the basis for incident heart
ailure cases in the future. Furthermore, depending
n the population studied and the cutoff chosen to
efine LVSD, approximately 2% to 8% of adults
ave LVSD, of whom approximately one-half have
o prior or current history of heart failure (Table 1).
en are 2 to 3 times more likely to be affected with
strong age predilection. In selected high-risk
roups such as patients with vascular disease or
iabetes mellitus, up to 20% may have LVSD (11).
hat Are theMorbidity andMortality Associated
ith Asymptomatic LVSD?
ongitudinal cohort studies have demonstrated a
- and 8-fold increased risk of developing heart
ailure in individuals with mild and moderate to
evere asymptomatic LVSD, respectively (12). In
he SOLVD (Studies of Left Ventricular
ysfunction)-Prevention study, 15.8% of individu-
ls with asymptomatic LVSD died within 37
onths, with approximately 90% of these being
ardiovascular deaths (13). In the Framingham
ohort, individuals with asymptomatic LVSD had a
0% higher risk of dying (Fig. 2) (12). Most of
hese deaths were attributed to vascular disease
40% coronary artery disease, 21% other vascular
isease), with 43% of the coronary artery disease
eaths being sudden. Importantly, 56% of the
ndividuals with asymptomatic LVSD who died did
ot develop antecedent heart failure, indicating that
aiting for someone to develop symptomatic heart
ailure may be a missed opportunity to intervene
nd potentially avoid premature death.
anWe Improve Outcomes in Individuals With
symptomatic LVSD?
tudies in subjects with LVSD following myocar-
ial infarction with or without heart failure man-
ate the use of beta-adrenergic receptor blockers
nd either angiotensin-converting enzyme (ACE)
nhibitors or angiotensin receptor blockers to retard
rogressive adverse LV remodeling and improve
utcomes (14). There is also randomized controlledB B R E V I A T I O N S
N D A C R O N YM S
CE angiotensin-converti
nzyme
CG electrocardiogram
CU hand-carried cardiac
ltrasound
V left ventricular
VSD left ventricular systorial evidence from the SOLVD-Prevention inves-
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423igators that ACE inhibitors reduced the combined
nd point of death or hospitalization for heart
ailure in patients with asymptomatic LVSD over 3
ears of follow-up (13). Despite most subjects being
rescribed open-label ACE inhibitors after the
tudy was completed, there was a significant mor-
ality benefit over 11 years in those subjects who
ere randomized to receive ACE inhibitor therapy
n the original study (Fig. 3) (15). This is particu-
Table 1. Prevalence of LVSD in Community Surveys Involving M
Study (Ref #)
Sample
Size
Age Range
(yrs)
Mean
(yrs
Gardin et al. (17) 5,201 65 73
(U.S.)
McDonagh et al. (19) 1,467 25–74 50
(Scotland)
Schunkert et al. (20) 1,566 25–75 50
(Germany)
Mosterd et al. (21) 2,267 55–95 66
(the Netherlands)
Davies et al. (22) 3,960 45 61
(England)
Devereux et al. (18) 3,184 45–74 60
(U.S.)
Redﬁeld et al. (23) 2,042 45 63
(U.S.)
Abhayaratna et al. (24) 1,275 60–86 69
(Australia)
Target
Population
Randomized Trial
Ra
Patient
Outcomes
Treatment
Cases
Detected
Patient
Outcomes
Treatment
Cases
Detected
Old TestNew Test
P
Cases
Detected
New Test
Accuracy
*Cases d
  may not
Figure 1. Trial Evidence Versus Linked Evidence of Test Accurac
Ideally, the impact of a diagnostic test on clinical outcomes is direc
evidence from randomized controlled trials that treatment of cases
dence from diagnostic accuracy studies to infer clinical effectivenes
same spectrum of disease as the subjects in the treatment efﬁcacyEF  ejection fraction; FS  fractional shortening; LVSD  left ventricular systolic darly relevant given that most individuals with
VSD in the community are not taking ACE
nhibitors (16). Furthermore, in patients with vas-
ular disease, antiplatelet therapy, statins, and re-
ascularization may reduce the risk of recurrent
schemic events and subsequent adverse LV remod-
ling (14).
Given that LV ejection fraction usually measured
ith echocardiography is used to determine eligi-
Than 1,000 Subjects
LVSD Deﬁnition
Prevalence
(%)
Proportion
Symptom-Free (%)
Abnormal 3.7 —
EF30% 2.9 48
EF35% 7.7 77
EF48% 2.7 42
FS25% 3.7 60
EF40% 1.8 47
EF50% 5.3 61
EF40% 2.9 72
EF54% 14.0 90
EF40% 2.0 47
EF50% 6.0 76
EF40% 2.1 22
EF50% 5.9 59
Test Accuracy Study Plus
mized Trial of Treatment Efficacy
plusgetlation
Cases
Detected
Old Test
Accuracy
Cases
Detected*
ted by the new and old test
w similar response to treatment
Patient
Outcomes
Patient
Outcomes
No
TreatmentTreatment
d Treatment Efﬁcacy
ssessed in a randomized controlled trial. Alternatively, if there is
s to better outcomes, it may be appropriate to link this to evi-
ovided the cases identiﬁed by the diagnostic test represent the
ies. Reprinted, with permission, from Lord et al. (9).ore
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424ility status in treatment efficacy studies and as the
eference standard in diagnostic accuracy studies, it
ould seem reasonable to infer clinical effectiveness
ith strategies that improve our ability to detect
VSD. However, most individuals with asymp-
omatic LVSD in the community would not have
een eligible for the SOLVD-Prevention trial, in
Years
p<0.0001
2 4 6 8 10 12
No ALVD
Mild ALVD
Mod/sev ALVD
Systolic CHF
Kaplan-Meier Curves for Survival of Participants From the
m Study
nt group consisted of subjects with normal left ventricular (LV)
ction (ejection fraction [EF] 50%) and no history of congestive
e (CHF). Reprinted, with permission, from Wang et al. (12). Mild
ild asymptomatic LV systolic dysfunction (EF 40% to 50%); Mod/
 moderate to severe asymptomatic LV systolic dysfunction (EF
stolic CHF  CHF with EF 50%.
at Risk
2111 1917 1736 1533 1348 1010 319
2117 1901 1664 1457 1252 935 297
p=0.001
Placebo
Enalapril
In-trial
period
12-year
Trial Termination
47
41
5-year
77
73
84
86
Survival Curves for the Enalapril and Placebo Groups in the
evention Trial
ost subjects being prescribed open-label angiotensin-converting
hibitors after the original study was completed at 3 years of
there was a mortality beneﬁt seen at 11 years in those subjects
randomized to enalapril in the original study. Numbers beside the
ote the percentage of survivors at termination, 5 years after ran-
, and 12 years after randomization, calculated by the Kaplan-d
hod. Reprinted, with permission, from Jong et al. (15).hich middle-aged men with coronary artery dis-
ase and moderate to severe LVSD dominated (13).
hat being said, it is generally accepted that this
ndication for ACE inhibitors should be applied
roadly, given the consistent demonstration of efficacy
n studies that enrolled subjects with LVSD (14).
ow ShouldWe Screen for Asymptomatic LVSD?
n asymptomatic populations with low disease prev-
lence, diagnostic screening tests with high speci-
city and positive predictive value are preferred to
llow a rule-in strategy, thereby minimizing false
ositives and unnecessary downstream testing. The
ow prevalence of LVSD in the general community
17–24), the inability of a physical examination to
eliably detect LVSD (25), and the limited avail-
bility of standard echocardiography mandate a
elective approach to identify which individuals
hould undergo echocardiography. Three options
hat have been widely evaluated are the use of
linical risk factors, the 12-lead electrocardiogram
ECG), and plasma natriuretic peptide levels.
The use of clinical characteristics incorporated
nto a multivariable logistic regression model to
etect individuals with LVSD applied to the Fram-
ngham cohort had an area under the receiver-
perator-characteristic curve of 0.75 in men and
.72 in women; however, this model did incorpo-
ate 12-lead ECG findings and would be difficult to
se in clinical practice (26). The 12-lead ECG has
een shown to be highly sensitive in identifying
VSD in some but not all studies (27). However, it
acks the specificity and therefore the positive pre-
ictive value to be useful as a screening tool, with
ost studies reporting specificities below 80% (27).
In symptomatic patients, recent meta-analyses
ave demonstrated that plasma natriuretic peptides
re better indicators of clinical heart failure than of
VSD (28,29). This reflects their correlation with
aised intracardiac filling pressure, which occurs in
VSD and various other forms of heart disease
30). Studies that have focused on the isolated
etection of LVSD in asymptomatic individuals
ave been heterogeneous, with indications of pub-
ication bias in at least 1 systematic review (Table 2)
27–29). In part, this may be explained by the
ifferent populations evaluated, the various assays
nd thresholds used to define abnormal levels, and
he different cutoffs used to define the reference
tandard (i.e., “any” or “moderate to severe”
VSD). In an economic evaluation based upon theSu
rv
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al
0.0
0.2
0.4
0.6
0.8
1.0
0
Figure 2.
Framingha
The refere
systolic fun
heart failur
ALVD  m
Sev ALVDNumber 
Enalapril 
Placebo 
0
10
20
30
40
50
60
70
80
90
100
Su
rv
iv
or
s 
(%
)
Figure 3.
SOLVD-Pr
Despite m
enzyme in
follow-up,
who were
curves den
domizationiagnostic performance of plasma natriuretic pep-
t
o
t
L
l
p
m
p
t
l
a
s
1
p
k
n
i
R
n
“
a
o
d
w
p
t
G
t
a
f
s
H
t
G
e
h
c
h
o
d
p
i
c
t
a
o
s
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 3 , N O . 4 , 2 0 1 0
A P R I L 2 0 1 0 : 4 2 1 – 8
Atherton
Screening for LVSD
425ides in the Framingham cohort (26) and health
utcome data extrapolated from randomized con-
rolled trials (13), it appeared that screening for
VSD may be cost effective, provided the preva-
ence of LVSD was at least 1% in the target
opulation (Fig. 4) (31). However, by far, the
ajority of individuals with abnormal natriuretic
eptide levels will have normal LV systolic func-
ion, which limits the use of natriuretic peptide
evels as a screening tool for LVSD in asymptom-
tic individuals (32). Attempts to improve the
pecificity by incorporating clinical variables, the
2-lead ECG, measurement of urinary natriuretic
eptide levels, and additional inflammatory biomar-
ers have met with variable success (27,33,34).
It has been argued that limiting the use of
atriuretic peptides to the detection of LVSD
gnores their full diagnostic and prognostic utility.
aised natriuretic peptide levels in individuals with
ormal LV systolic function (who are labeled as
false positives”) may indicate other pathology such
s LV diastolic dysfunction, atrial fibrillation, cor-
nary artery disease, valvular heart disease, or car-
iomyopathy (30,32). However, it is not clear
hether further investigation and treatment of such
Table 2. A Systematic Review of Diagnostic Accuracy Studies of
Standard Used
Outcome n DOR (95% CI)
Heart failure 11 41.5 (23.3–73.9)
9* 28.9 (20.6–40.6)
LVSD 25 7.83 (5.12–12.0)
*Excluding 2 outlier studies. Modiﬁed, with permission, from Latour-Perez et al
AUC  area under the receiver-operator characteristic curve; CI  conﬁdence
SE  standard error.
In
cr
em
en
ta
l C
-E
($/
QA
LY
 
G
ai
ne
d)
Prevalence of LV 
Base case (Women0
20,000
40,000
60,000
80,000
0% 1% 2
Figure 4. Impact of Prevalence of Low EF on the Cost Effectiven
Echocardiography in Those With a Positive Test
The cost-effectiveness (C-E) ratio drops below $100,000 per quality-
below $50,000 at a prevalence over 1%. For any given prevalence o
B-type natriuretic peptide (BNP) levels is slightly greater for women
women (BNP vs. no screen). Reprinted, with permission, from Heidenreiathology in the context of screening in an asymp-
omatic population will lead to better outcomes.
iven that the accepted reference standard to iden-
ify subjects with LVSD is an imaging method,
nother approach to screening is to perform a
ocused and limited imaging study to answer the
pecific question being asked.
and-Carried Cardiac Ultrasound (HCU) Devices
o Screen for Asymptomatic LVSD
iven the limited availability and cost of standard
chocardiography, portable HCU devices providing
igh image quality at substantially reduced capital
ost have been developed, with some recent hand-
eld devices weighing 1 kg. Although a number
f studies have addressed how HCU may reduce
iagnostic error when performed in addition to
hysical examination (35), there has been growing
nterest in evaluating its role as a screening tool in
ommunity-based populations (36–38). The sensi-
ivity and specificity of HCU to identify LVSD is
pproximately 90% when performed by experienced
perators (36–38). In a consecutive series of 533
ubjects, the comparative diagnostic performance
ype Natriuretic Peptide According to the Reference
p Value
omogeneity) AUC (SE)
p Value
(Publication Bias)
0.001 0.93 (0.03) 0.18
0.30 0.93 (0.02) 0.82
0.001 0.75 (0.03) 0.001
).
vals; DOR  diagnostic odds ratio; LVSD  left ventricular systolic dysfunction;
tolic Dysfunction (EF<35%)
Base case (Men)
3% 4% 5%
of Screening for Men and Women Using BNP Followed by
sted life year (QALY) gained at a prevalence over 0.5% and drops
sease, the C-E ratio is lower for women because the accuracy of
n men. Open circles  men (BNP vs. no screen); closed circles B-T
(H
. (29
interSys
)
%
ess
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f di
thech et al. (31). EF  ejection fraction; LV  left ventricular.
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426avored HCU compared with the 12-lead ECG and
lasma natriuretic peptide levels, driven largely by
ts higher specificity (Table 3) (38). A further small
mprovement in specificity was achieved by per-
orming HCU only in those individuals who had
ither an abnormal 12-lead ECG or elevated natri-
retic peptide levels, but at the expense of a reduc-
ion in sensitivity. The reduction in unnecessary
ownstream testing driven by the higher positive
redictive value of HCU makes this a cost-effective
ethod to determine which patients should have a
tandard echocardiogram, especially when per-
ormed in subjects at the highest risk of developing
VSD, such as those with vascular disease, diabetes
ellitus, or previous heavy alcohol exposure (Table
) (38).
imitations of the Evidence
he best method to screen for asymptomatic LVSD
s still not clear, with multiple or sequential biomar-
er strategies and HCU holding the most promise
33,34,36–38). HCU appears to be cost effective;
owever, a number of questions remain. What is
he ideal target population? Screening high-risk
opulations appears most appropriate (38), but
hat is the best method to identify these individu-
ls, and should we include age and sex descriptors?
ho should perform HCU? The procedure is
ighly dependent on the operator, and its wide-
pread application may be limited by the finite
umber of experienced sonographers. Operators
ith limited echocardiography experience have
een trained in standardized programs as short as 3
ours to perform and interpret focused echocardio-
rams with moderate sensitivity to detect LVSD;
owever, these studies have largely involved physi-
tic Accuracy and Cost Effectiveness of the 12-Lead ECG, NTproBN
raphy as the Reference Standard
tegy
General Population (n  734
Sensitivity Speciﬁcity
Cost per C
Detec
92 78 1,
al 80 88 1,
l abnormal 96 72 2,
el abnormal 76 94 1,
93 97 1,
G abnormal 87 98
TproBNP level abnormal 87 98
3 consecutive subjects. †High-risk refers to individuals with a history of ischemic h
odiﬁed, with permission, from Galasko et al. (38).
; HCU  hand-carried cardiac ultrasound; LVSD  left ventricular systolic dysfunctionians and medical students, who are unlikely to be
nvolved in widespread screening programs (39).
onetheless, this could allow for opportunistic
creening of high-risk patients when they present
or clinical evaluation. Furthermore, in a small
tudy of diabetic outpatients, nurses trained to use
CU correctly identified all cases of LVSD, al-
hough the false-positive rate was relatively high
40). Whichever method is chosen, appropriate
uality control processes need to be established to
nsure consistent training, skills maintenance, and
cceptable diagnostic accuracy.
Should we restrict screening to the detection of
symptomatic moderate to severe LVSD? Mild
VSD and diastolic dysfunction are also associated
ith increased morbidity and mortality (5,12).
owever, it is not clear whether treating this would
ead to better outcomes in asymptomatic popula-
ions. How often should we screen? This will drive
ost effectiveness and will be influenced by the
ncident rate of LVSD in the target population.
inally, screening for asymptomatic LVSD has not
een evaluated in a randomized controlled trial;
owever, a linked evidence approach seems reason-
ble, given the evidence that we can improve
utcomes in subjects with asymptomatic LVSD
13–15).
onclusions
he impact of treating symptomatic heart failure on
verall disease burden is likely to be limited unless
reatment is combined with methods to reduce the
requency of incident heart failure in the commu-
ity. One method to do this is to screen for
ecognized precursors of heart failure such as
symptomatic LVSD. A number of strategies have
nd HCU,* or Their Combination in Detecting LVSD, With
High-Risk Group (n  761)†
of LVSD
(€) Sensitivity Speciﬁcity
Cost per Case of LVSD
Detected (€)
90 64 1,006
76 70 1,096
94 49 1,485
73 85 1,104
97 93 683
83 96 649
70 97 712
disease, diabetes mellitus, peripheral vascular disease, cerebrovascular disease,Table 3. The Diagnos P, a
Standard Echocardiog
Stra
)
ase
ted
ECG abnormal 614
NTproBNP level abnorm 501
ECG or NTproBNP leve 412
ECG and NTproBNP lev 912
HCU abnormal 101
HCU abnormal after EC 884
HCU abnormal after N 913
*HCU was performed in 53 eart
or heavy alcohol usage. M; NTproBNP  N-terminal pro–B-type natriuretic peptide.
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427een evaluated, including the use of clinical scores,
he 12-lead ECG, natriuretic peptide levels, and
ore recently, HCU. The HCU holds promise as a
creening tool in asymptomatic subjects, with a
igh specificity if HCU is performed by experi-
nced sonographers. However, the technique is
ighly operator dependent, which may limit its
roader application in resource-constrained envi-
onments. That being said, it seems likely thatand when do we need randomized Age Ageing 2004;3reater impact on disease burden than our current
pproach of waiting for individuals to develop
linical heart failure before deciding who and when
o treat.
eprint requests and correspondence: Dr. John J. Ather-
on, Royal Brisbane and Women’s Hospital, Butterfield
treet, Herston, Queensland, QLD 4006 Australia.creening for asymptomatic LVSD will have a E-mail: john_atherton@health.qld.gov.au.1
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